Dr. Mahler is Founder, CEO and Board Member at ten23 health AG, the human-centric and
sustainable pharmaceutical development partner.
Previously, Dr. Mahler has been leading the Drug Product Services Business Unit at Lonza AG, leading
Pharmaceutical Development & Supplies Biologics at Roche (Basel), and as Principal Scientist & CMC
Team leader Erbitux at Merck KGaA.
He is also adjunct faculty at the Universities of Frankfurt (Germany) and Basel (Switzerland), serves as
Scientifc Expert (Ph.Eur.) at EDQM and as Board Member for Bionter & KriyaBio.
He studied Pharmacy & holds in Ph.D. in Toxicology from the University of Mainz.
About ten23 health
ten23 health, headquartered in Basel, Switzerland, was founded in 2021. We are the human-centric
and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we
develop, manufacture, and test tomorrow’s medicines. We support our clients in developing
differentiated, stable, usable, and safe injectable treatment options for patients.
ten23 health combines the latest scientific findings with our proven and tested world-class industry
and regulatory expertise to forge new paths for supporting our clients. We provide our innovative
services in a fair and sustainable manner, respecting people’s health and the future of our planet.